Navigation Links
Failure Rate of DePuy ASR XL Hip Implant Rising

FORT WORTH, Texas, March 31, 2011 /PRNewswire/ -- Recent information presented at the British Hip Society Annual Conference held from March 2 -4, 2011 indicates a rise in the failure rate of the DePuy ASR XL Acetabular Hip Replacement System which was manufactured and marketed by DePuy Orthopaedics, Inc., a subsidiary of Johnson & Johnson.  The British Orthopaedic Association has released a summary of the results of the study presented, stating that the early failure rates "range from 21% revision rate at 4 years (potentially rising to 35% if all currently known painful implants progress to revision) to 49% at 6 years for the ASR XL device."  This summary was included in an article published on the British Orthopaedic Association's website entitled "Large Diameter Metal on Metal Bearing Total Hip Replacements."

"The DePuy ASR XL Hip Replacement Systems were first sold by DePuy and Johnson & Johnson in the UK and other countries in 2003. The ASR XL was sold in the United States beginning in 2005. It now appears that patients who received these implants are experiencing failures at a staggering rate. The device was recalled by DePuy Orthopaedics, Inc. on August 24, 2010. Sales of a medical product with a failure rate of 49% at six years is unconscionable. Profits over patient safety is unacceptable," said attorney John David Hart of the Law Offices of John David Hart who represents many individuals in the United States who have been injured as a result of this defective hip replacement system.

DePuy identified reasons for the failure of the hip replacement system as component loosening, component malalignment, infection, fracture of the bone, dislocation, metal sensitivity and pain. Additional complications from the DePuy ASR XL Acetabular Hip Replacement System may include increased metal ion levels in the blood, bone staining, necrosis, swelling, nerve damage, tissue damage and/or muscle damage.

The Law Offices of John David Hart is a group of experienced and dedicated legal professionals working to protect the rights of people wronged by the acts of others.  Across the country, the firm represents individuals in cases of catastrophic personal injury, wrongful death, dangerous drugs and medical products, automobile and truck accidents and oil and gas litigation.  For more information, please contact John David Hart at 800.961.4278 or or visit

SOURCE The Law Offices of John David Hart
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Qualitest Receives FDA Approval for Toresmide Tablets (Generic Demadex®) 5 mg, 10 mg, 20 mg, 100 mg, for the Treatment of Edema Associated with Congestive Heart Failure, Renal Disease, or Hepatic Disease
2. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
3. Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
4. Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
5. Success Factors and Failure Points in Biopharmaceutical Product Launches
6. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
7. FDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products
10. NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events
11. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
Post Your Comments:
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical ...  - 22 nd April 2016. --> --> ... --> -->   --> ... aging population and the government back up, the Medical Device is one of ... States . With the aging population and the government back up, the ...
(Date:11/30/2015)... 30, 2015 Nevro Corp. (NYSE: NVRO ), ... solutions for the treatment of chronic pain, today announced that ... Patent and Trademark Office (USPTO) has denied instituting an ... (the ,102 patent).  --> ... Scientific Corporation filed two petitions challenging the validity of certain ...
(Date:11/30/2015)... , Nov. 30, 2015 ... of the "Orphan Drugs Market 2015-2019" ... ) has announced the addition of the ... offering. --> Research and Markets ( ... "Orphan Drugs Market 2015-2019" report to ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum of Science & ... a new era of publicly accessible automated technology. Now, by popular demand, the ... guests an up-close look at the shuttle at MOSI’s main entrance. This experience ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals ... So why is it a national news story when Donald Trump makes disparaging remarks ... because appearances count more than anyone wants to admit when it comes to how ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... course in Dallas, TX, on January 29 and 30, 2016. The course welcomes ... functions of their practices, to learn how to better succeed in the modern ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant ... at Georgia State University. , Their study showed that small molecule analogs that ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies specializes in orthodontics ... visit Dr. Margulies to experience the best available orthodontic experience in the area. ... Top Dentist"! , Orthodontics is the branch of dentistry that specializes in the diagnosis, ...
Breaking Medicine News(10 mins):